Clinical effect analysis of ultrasound-guided percutaneous radiofrequency ablation in the treatment of ovarian mature cystic teratoma
10.3760/cma.j.cn131148-20240220-00103
- VernacularTitle:超声引导下经皮射频消融治疗卵巢成熟性囊性畸胎瘤的临床效果
- Author:
Zinan ZHAO
1
;
Gang DONG
;
Tingting LIU
;
Shanshan ZHANG
;
Shuo WANG
;
Mengfan PENG
;
Na LI
Author Information
1. 郑州大学第一附属医院超声科，郑州 450000
- Keywords:
Ultrasound-guided;
Radiofrequency ablation;
Ovarian mature cystic teratoma
- From:
Chinese Journal of Ultrasonography
2024;33(8):725-730
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the safety and efficacy of ultrasound-guided percutaneous radiofrequency ablation in the treatment of ovarian mature cystic teratoma.Methods:A total of 35 patients with mature cystic teratoma of the ovary diagnosed and treated in the ultrasound intervention room of the First Affiliated Hospital of Zhengzhou University from May 2020 to May 2023 were selected retrospectively. According to the inclusion criteria, 23 patients who underwent ultrasound-guided percutaneous radiofrequency ablation were enrolled in this study, and the therapeutic effect and the reduction rate of the ablation lesions 1, 3 and 6 months after surgery were observed. The occurrence of intraoperative and postoperative complications was observed. The changes of serum follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol (E 2) and anti-Mullerian hormone (AMH) were compared before surgery, 3 days, and 1, 3 and 6 months after surgery. Results:All 23 patients underwent radiofrequency ablation successfully, and the complete ablation rate was 100%. The reduction rates were (29.95±13.89)%, (51.45±17.62)% and (73.82±23.63)% at 1, 3 and 6 months, respectively. There were no serious complications during and after operation. There were no significant differences in serum levels of FSH, LH, E 2 and AMH before surgery, 3 days, and 1, 3 and 6 months after surgery (all P>0.05). Conclusions:Ultrasound-guided percutaneous radiofrequency ablation is a safe, minimally invasive and effective treatment for ovarian mature cystic teratoma.
